Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA Gives Nod To Purdue Pharma New Formulation Of OxyContin
Purdue Pharma said that the drug is made to slowly release the potent opioid oxycodone to treat patients who require a continuous, around-the-clock opioid analgesic for management of
Purdue Pharma said that the drug is made to slowly release the potent opioid oxycodone to treat patients who require a continuous, around-the-clock opioid analgesic for management of
Vaisala claimed that Humicap HMP110 encompasses the complete humidity range at temperatures from -40ºC to 80ºC and is designed to be small in size, compact and easy to
The study showed that DepoVax platform promotes antigen specific immune responses, however, unlike the control vaccine, the DepoVax formulation does not induce problematic immune regulatory responses. DPX-0907 is
As per the terms of the agreement, AnaptysBio is expected to be responsible for generating novel antibodies using its proprietary somatic hypermutation (SHM) technology platform. Reportedly, Antibodies generated
Cloxacillin sodium, a generic form Cloxapen, in finished dosage form is listed in China’s National Medical Reimbursement Insurance List and thus is eligible for reimbursement by the government’s
Specifically, NICE’s FAD recommends Alimta as an option for the maintenance treatment of people with locally advanced or metastatic non-small cell lung cancer with other than predominantly squamous
Zegerid OTC is the OTC proton pump inhibitor (PPI) product with two active ingredients, omeprazole, a PPI, and sodium bicarbonate. The sodium bicarbonate acts as a buffer to
The Sysmex XT-4000i provides 34 parameters, including the advanced clinical parameters, IG (Immature Granulocyte) and RET-He (Reticulocyte Hemoglobin Equivalent) and a Body Fluid specific mode. It utilizes Sysmex’s
Ser-120 is a new, nasally administered clinical drug candidate in Phase III clinical trials being investigated for its safety and efficacy in relieving the symptoms of nocturia and
IFN-Beta, which is indicated for the treatment of multiple sclerosis (MS), is currently marketed by Merck Serono as Rebif and by Biogen Idec as Avonex. Prolor Biotech has